Literature DB >> 16048455

Continuation electroconvulsive therapy for relapse prevention in middle-aged and elderly patients with intractable catatonic schizophrenia.

Kazumasa Suzuki1, Shuichi Awata, Takehisa Takano, Yukio Ebina, Hitoshi Iwasaki, Hiroo Matsuoka.   

Abstract

The authors have previously studied the short-term effect of the first acute electroconvulsive therapy (ECT) course (phase 1 study) on intractable catatonic schizophrenia and the 1-year relapse rate after response to the acute ECT (phase 2 study) in middle-aged and elderly patients. Results indicated that, although acute ECT has an excellent short-term effect, the 1-year relapse rate after response to acute ECT is high despite the use of continuation neuroleptics. In the present prospective study the effect was explored of continuation ECT with neuroleptics on the prevention of relapse after response to a second acute ECT course in the relapsed participants of the phase 2 study. The present study included seven consecutive patients > 45 years of age with catatonic schizophrenia (Diagnostic and Statistical Manual of Mental Disorders (4th edn; DSM-IV) who relapsed (despite the use of neuroleptics) within 1 year after response to the first acute ECT course, and then responded to the second acute ECT course. The patients were given continuation ECT combined with neuroleptics; four ECT sessions at weekly intervals, then four ECT sessions every 2 weeks, then three ECT sessions every 4 weeks. Clinical symptoms were evaluated by means of the Brief Psychiatric Rating Scale (BPRS) weekly for 48 weeks or until relapse. Relapse was defined as a BPRS score of at least 37 for 3 consecutive days. Three out of the seven patients (42.9%) had a sustained response to ECT during the 1-year follow-up period. In the seven patients the probability of relapse within 1 year under treatment with neuroleptics alone (phase 2 study) was statistically higher than that under continuation ECT combined with neuroleptics (present study). No statistical differences were seen between the phase 2 study and the present study in the severity of psychiatric symptoms, global social function, the number of acute ECT sessions or the dosage of neuroleptics. No patient experienced a severe cognitive or physical adverse effect resulting from continuation ECT. Continuation ECT with neuroleptics is an efficacious and safe treatment for maintaining a response in middle-aged and elderly patients with intractable catatonic schizophrenia who have relapsed after a positive response to acute ECT despite the use of continuation neuroleptics.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16048455     DOI: 10.1111/j.1440-1819.2005.01402.x

Source DB:  PubMed          Journal:  Psychiatry Clin Neurosci        ISSN: 1323-1316            Impact factor:   5.188


  14 in total

Review 1.  Brain stimulation in the treatment of late-life severe mental illness other than unipolar nonpsychotic depression.

Authors:  Angela Y Liu; Tarek K Rajji; Daniel M Blumberger; Zafiris J Daskalakis; Benoit H Mulsant
Journal:  Am J Geriatr Psychiatry       Date:  2013-07-23       Impact factor: 4.105

Review 2.  Continuation and maintenance electroconvulsive therapy for mood disorders: review of the literature.

Authors:  Georgios Petrides; Kristen G Tobias; Charles H Kellner; Matthew V Rudorfer
Journal:  Neuropsychobiology       Date:  2011-07-29       Impact factor: 2.328

Review 3.  Prevalence of Catatonia and Its Moderators in Clinical Samples: Results from a Meta-analysis and Meta-regression Analysis.

Authors:  Marco Solmi; G Giorgio Pigato; Beatrice Roiter; Argentina Guaglianone; Luca Martini; Michele Fornaro; Francesco Monaco; Andrè F Carvalho; Brendon Stubbs; Nicola Veronese; Christoph U Correll
Journal:  Schizophr Bull       Date:  2018-08-20       Impact factor: 9.306

Review 4.  Management of schizophrenia in late life with antipsychotic medications: a qualitative review.

Authors:  Takefumi Suzuki; Gary Remington; Hiroyuki Uchida; Tarek K Rajji; Ariel Graff-Guerrero; David C Mamo
Journal:  Drugs Aging       Date:  2011-12-01       Impact factor: 3.923

5.  Electroconvulsive therapy for treating schizophrenia: a chart review of patients from two catchment areas.

Authors:  Diana Kristensen; Jeanett Bauer; Ida Hageman; Martin Balslev Jørgensen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-12-05       Impact factor: 5.270

Review 6.  Electroconvulsive Therapy in Psychiatric Disorders: A Narrative Review Exploring Neuroendocrine-Immune Therapeutic Mechanisms and Clinical Implications.

Authors:  Milagros Rojas; Daniela Ariza; Ángel Ortega; Manuel E Riaño-Garzón; Mervin Chávez-Castillo; José Luis Pérez; Lorena Cudris-Torres; María Judith Bautista; Oscar Medina-Ortiz; Joselyn Rojas-Quintero; Valmore Bermúdez
Journal:  Int J Mol Sci       Date:  2022-06-22       Impact factor: 6.208

7.  Management and outcomes of catatonia: A prospective study in urban South Africa.

Authors:  Zukiswa Zingela; Louise Stroud; Johan Cronje; Max Fink; Stephan van Wyk
Journal:  SAGE Open Med       Date:  2022-06-20

8.  Current electroconvulsive therapy practice and research in the geriatric population.

Authors:  Nancy Kerner; Joan Prudic
Journal:  Neuropsychiatry (London)       Date:  2014-02

Review 9.  Catatonia in autism: implications across the life span.

Authors:  Angelina Kakooza-Mwesige; Lee E Wachtel; Dirk M Dhossche
Journal:  Eur Child Adolesc Psychiatry       Date:  2008-04-21       Impact factor: 4.785

Review 10.  Electroconvulsive therapy and its different indications.

Authors:  Thomas C Baghai; Hans-Jürgen Möller
Journal:  Dialogues Clin Neurosci       Date:  2008       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.